Regeneron Pharmaceuticals (REGN) Upgraded to Strong-Buy at Zacks Investment Research


The brokerage presently has a $380.00 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target indicates a potential upside of 14.05% from the stock's current price.



from Biotech News